Last reviewed · How we verify
NCT04174898: REGEN
MSC Infusion for Anti-aging and Regenerative Therapy
Phase 1 trial testing human Mesenchymal Stem Cell (MSC) infusion therapy in Aging Well in 100 participants. Status unknown.
14 April 2021
Quick facts
| Lead sponsor | Landmark Medical Centre Sdn Bhd |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 100 |
| Start date | 15 April 2020 |
| Primary completion | 14 April 2021 |
| Estimated completion | 14 April 2022 |
| Sites | 1 location across Malaysia |
Drugs / interventions tested
- human Mesenchymal Stem Cell (MSC) infusion therapy — full drug profile →
Conditions studied
- Aging Well — all drugs for Aging Well →
- Regenerative Medicine — all drugs for Regenerative Medicine →
Sponsor
Landmark Medical Centre Sdn Bhd — full company profile →
Who can join
18 and older, any sex, with Aging Well or Regenerative Medicine. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the safety and efficacy of human Mesenchymal Stem Cell (hMSC) infusion therapy, in preserving general wellness and ameliorating or reversing the effects of aging in our study population
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Therapeutic Properties of Mesenchymal Stromal/Stem Cells: The Need of Cell Priming for Cell-Free Therapies in Regenerative Medicine.
Miceli V, Bulati M, Iannolo G, Zito G, et al · · 2021 · cited 120× · PMID 33466583 · DOI 10.3390/ijms22020763 -
Recent clinical trials with stem cells to slow or reverse normal aging processes.
Garay RP. · · 2023 · cited 14× · PMID 37090485 · DOI 10.3389/fragi.2023.1148926 -
Emerging Landscape of Mesenchymal Stem Cell Senescence Mechanisms and Implications on Therapeutic Strategies.
Wang J, Zhang M, Wang H. · · 2024 · cited 13× · PMID 39144566 · DOI 10.1021/acsptsci.4c00284
Verify or expand the search:
- PubMed search for NCT04174898
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Aging Well
Currently open trials in the same condition.
- NCT06507189 — Multidimensional Predictive Modeling to Understand Mechanisms of Exercise Response Heterogeneity in Older Adults (M3AX) · NA · recruiting
- NCT05910619 — Transcranial Pulse Stimulation of the Brain · NA · recruiting
- NCT06204562 — Feasibility and Effects of Laughter-imitation Therapy (LIT) · NA · active not recruiting
- NCT05920733 — Healthy Lifetime - Phase 2 · NA · recruiting
- NCT06217601 — Impact Evaluation of the Digital Connect Project for Homebound Older Adults · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04174898 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Landmark Medical Centre Sdn Bhd
- Last refreshed: 22 November 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04174898.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing